网MetaEasy:为比较有效性研究提供快速和用户友好的网络元分析 (NMA)
János Tibor Fekete1,2, András Komócsi3, Balázs Győrffy1,2,4
1Department of Bioinformatics, Semmelweis University, Budapest, Hungary.
British journal of pharmacology
|February 23, 2026
概括
网MetaEasy是一个用户友好的网络平台,可以快速轻松地进行网络元分析 (NMA). 它简化了复杂的统计分析,使先进的证据合成能够让更多的药理学研究人员接触到.
科学领域:
- 药理学和生物统计学
- 证据综合和元分析
背景情况:
- 网络元分析 (NMA) 对于比较多种治疗方法至关重要,但需要专门的统计专业知识和软件.
- 对于许多研究人员来说,NMA的复杂性和可访问性障碍阻碍了其更广泛的采用.
研究的目的:
- 介绍NetMetaEasy,这是一个基于Web的平台,旨在为用户友好地执行和可视化网络元分析而设计.
- 降低执行NMA的技术障碍,使其在研究和临床指南中得到更广泛的应用.
主要方法:
- 网MetaEasy是一个R/Shiny平台,支持二进制,连续和总结效果数据.
- 它提供频率和贝叶斯的NMA与P-score和SUCRA排名.
- 使用netmeta和gemtc R包用于固定和随机效应模型,生成标准NMA输出.
主要成果:
- 该平台成功地在SGLT2抑制剂的数据集上对心血管结果进行了NMA.
- NetMetaEasy生成了所有标准的NMA输出,确定了有益的治疗方法,并且没有显示小研究偏差.
- 整个分析工作流程,从数据上传到准备解释的图表,都在几分钟内完成.
结论:
- 网MetaEasy为网络元分析提供了一个可访问的解决方案,简化数据处理,分析和可视化.
- 该平台有助于更广泛和更快速的药理学证据综合,特别是对于那些没有高级统计学培训的人来说.
更多相关视频
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
1.3K
08:32Neurovascular Network Explorer 2.0: A Simple Tool for Exploring and Sharing a Database of Optogenetically-evoked Vasomotion in Mouse Cortex In Vivo
Published on: May 4, 2018
6.8K
相关概念视频
01:20Study Designs in Epidemiology
1.2K
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
1.2K
01:16Bioequivalence: Overview
2.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.1K